#1 Clinical Trials Search in Europe

Degarelix

Degarelix, also known as FE200486, is a drug that has been extensively studied in clinical trials for the treatment of prostate cancer. This article summarizes key findings from various clinical trials investigating the efficacy, safety, and long-term effects of Degarelix in patients with prostate cancer. The trials explored different dosing regimens, administration methods, and compared Degarelix to other treatments, providing valuable insights into its potential as a therapeutic option for prostate cancer patients.

Table of Contents

What is Degarelix?

Degarelix is a medication primarily used in the treatment of prostate cancer. It’s also known by its brand name Firmagon and was previously referred to as FE200486 during its development stages[1][2]. Degarelix belongs to a class of drugs called gonadotropin-releasing hormone (GnRH) antagonists, which work by lowering the levels of certain hormones in the body, particularly testosterone[3].

How Degarelix Works

Degarelix works by blocking the action of a hormone called GnRH in the body. This blockage leads to a rapid decrease in the production of testosterone, a hormone that can stimulate the growth of prostate cancer cells. By lowering testosterone levels, Degarelix helps to slow down or stop the growth of prostate cancer[3].

Unlike some other prostate cancer treatments, Degarelix doesn’t cause an initial surge in testosterone levels before reducing them. This means it can start working to lower testosterone levels almost immediately after administration[2].

Conditions Treated with Degarelix

Degarelix is primarily used to treat:

  • Prostate Cancer: This is the main condition for which Degarelix is prescribed. It’s used in various stages of prostate cancer, including advanced stages[3].
  • Benign Prostatic Hyperplasia (BPH): Some research has explored the use of Degarelix in treating BPH, a non-cancerous enlargement of the prostate gland[4].

How Degarelix is Administered

Degarelix is given as a subcutaneous injection, which means it’s injected just under the skin. The injection is typically administered in the abdominal area. It’s usually given by a healthcare professional in a medical setting[2].

Dosage Information

The dosage of Degarelix can vary depending on the specific treatment plan and the patient’s response. However, a common dosing regimen includes:

  • Starting dose: 240 mg given as two 120 mg injections
  • Maintenance dose: 80 mg given every 28 days

Some studies have also explored different dosing schedules, including three-month dosing intervals[5]. It’s important to note that the exact dosage should always be determined by a healthcare provider based on individual patient factors.

Effectiveness of Degarelix

Clinical trials have shown Degarelix to be effective in rapidly lowering testosterone levels in patients with prostate cancer. Some key findings include:

  • Degarelix can reduce testosterone to castration levels (≤0.5 ng/mL) within 1-3 days for many patients[2].
  • It maintains testosterone suppression for extended periods with continued treatment[5].
  • Degarelix has shown effectiveness in reducing prostate-specific antigen (PSA) levels, a marker often used to monitor prostate cancer[2].

Potential Side Effects

Like all medications, Degarelix can cause side effects. Some potential side effects observed in clinical trials include:

  • Injection site reactions (such as pain, redness, or swelling)
  • Hot flashes
  • Weight changes
  • Changes in liver function tests
  • Fatigue
  • Changes in sexual function

It’s important to discuss potential side effects with your healthcare provider. They can provide more detailed information and help manage any side effects that may occur[6].

Ongoing Research and Future Directions

Research on Degarelix is ongoing, with studies exploring its use in various scenarios:

  • Combination Therapy: Some studies are investigating the use of Degarelix in combination with other prostate cancer treatments, such as abiraterone acetate[3].
  • Imaging Studies: Research is being conducted on how Degarelix might enhance the effectiveness of certain imaging techniques used in prostate cancer diagnosis and monitoring[7].
  • Long-term Effects: Ongoing studies are examining the long-term safety and effectiveness of Degarelix in prostate cancer treatment[8].

These ongoing studies may lead to new applications or improved treatment strategies using Degarelix in the future.

Aspect Details
Drug Name Degarelix (FE200486)
Condition Treated Prostate Cancer
Administration Method Subcutaneous Injection
Dosing Regimens Various, including monthly and three-month depot formulations
Primary Outcomes Testosterone suppression, PSA reduction, safety profile
Key Findings Effective testosterone suppression, rapid PSA reduction, generally well-tolerated
Long-term Studies Extension studies conducted to assess long-term safety and efficacy
Safety Monitoring Liver function tests, vital signs, body weight changes

FAQ

  • What is Degarelix and how does it work? Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of prostate cancer. It works by quickly suppressing testosterone production, which can help slow or stop the growth of prostate cancer cells.
  • What were the main objectives of the Degarelix clinical trials? The main objectives of the Degarelix clinical trials were to evaluate its efficacy in suppressing testosterone levels, assess its safety and tolerability, determine optimal dosing regimens, and compare its performance to other prostate cancer treatments.
  • How was Degarelix administered in the clinical trials? Degarelix was administered as a subcutaneous injection in various doses and schedules, including single doses, monthly doses, and three-month depot formulations. The trials explored different concentrations and dosing intervals to find the most effective regimen.
  • What were the primary outcomes measured in the Degarelix trials? The primary outcomes measured included testosterone suppression (to levels ≤0.5 ng/mL), time to testosterone castration, prostate-specific antigen (PSA) reduction, liver function tests, and the incidence of adverse events related to vital signs and body weight changes.
  • Were there any long-term studies on Degarelix? Yes, several extension studies were conducted to evaluate the long-term safety and tolerability of repeated doses of Degarelix in prostate cancer patients. These studies provided valuable information on the drug's effects over extended periods of treatment.

Ongoing Clinical Trials on Degarelix

  • Study on Docetaxel and Carboplatin-Docetaxel Combination for Prostate Cancer Patients Progressing After Olaparib Treatment

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium Bulgaria France Italy Lithuania Poland +1

  • Study on Darolutamide with Radiation Therapy for Patients with Intermediate Unfavorable Risk Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Degarelix and Drug Combination with Radiotherapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Spain

  • Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +4

  • Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

    Not recruiting

    3 1 1
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Metastatic Prostate Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Hungary Italy +4

  • Study on Prostate Cancer Treatment: Comparing Goserelin Acetate, Leuprorelin Acetate, Degarelix, and Apalutamide in Patients with Biochemical Progression After Surgery

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Belgium

  • Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Czechia France Germany Italy The Netherlands Poland +1

  • Study of [225Ac]Ac-PSMA-R2 for Men with Advanced Prostate Cancer Previously Treated or Not with 177Lu-PSMA Therapy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France

Glossary

  • Prostate Cancer: A type of cancer that develops in the prostate gland, which is part of the male reproductive system. It is one of the most common cancers in men.
  • Testosterone: The primary male sex hormone that plays a crucial role in the development and maintenance of male characteristics. In prostate cancer, lowering testosterone levels can help slow or stop cancer growth.
  • Castration: In the context of prostate cancer treatment, castration refers to reducing testosterone levels to very low levels, typically ≤0.5 ng/mL, either through surgical or medical means.
  • Prostate-Specific Antigen (PSA): A protein produced by the prostate gland. Elevated PSA levels may indicate prostate cancer or other prostate conditions. PSA is often used as a marker to monitor prostate cancer progression and treatment effectiveness.
  • Subcutaneous Injection: A method of administering medication by injecting it into the tissue layer between the skin and the muscle.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and the relationship between drug concentration and effect.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
  • Extension Study: A follow-up study that continues to evaluate the effects of a treatment after the initial clinical trial has ended, often focusing on long-term safety and efficacy.
  • Depot Formulation: A form of drug delivery where the medication is deposited in a localized mass, which slowly releases the active compound over an extended period.

References

  1. https://clinicaltrials.gov/study/NCT00215657
  2. https://clinicaltrials.gov/study/NCT00117949
  3. https://clinicaltrials.gov/study/NCT01751451
  4. https://clinicaltrials.gov/study/NCT00527488
  5. https://clinicaltrials.gov/study/NCT00116753
  6. https://clinicaltrials.gov/study/NCT00245466
  7. https://clinicaltrials.gov/study/NCT04391556
  8. https://clinicaltrials.gov/study/NCT00268892